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T1 Mapping by CMR in Cardiomyopathy:
A Noninvasive Myocardial Biopsy?
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qardiac magnetic resonance (CMR) is
evolving to be the imaging modality of
choice for differentiating the etiology of
cardiomyopathies. Its inherent 3-dimen-
ional nature enables accurate measurement of left
entricular (LV) volumes, mass, and ejection frac-
ion (1). Late gadolinium enhancement (LGE) is
sed to aid in the differentiation of ischemic from
onischemic cardiomyopathies, and in the setting
f the latter, can usually distinguish myocarditis,
arcoidosis, amyloidosis, and other infiltrative car-
iomyopathies based upon their distinct pattern
f enhancement (2). In addition, the newer tech-
ique of T1 mapping (3), typically performed af-
er gadolinium-based contrast agent administra-
ion, has proved useful in demonstrating increased
xtracellular volume in conditions such as hyper-
rophic cardiomyopathy and aortic stenosis, and
n these particular settings has been shown to cor-
elate well with histological markers of myocardial
brosis (4). Newer tissue mapping strategies, both
1 and T2, are quantitative techniques that offer
he promise of standardizing CMR measurements
f myocardial tissue properties, no longer leaving
he interpretation to the eye of the beholder (5).
A subset of cardiomyopathy patients, especially
hose with amyloidosis, often suffer from concom-
tant renal dysfunction and may not be candidates
or gadolinium due to concerns over nephrogenic
ystemic fibrosis (6). Thus, the ability to charac-
erize myocardial tissue without contrast would be
f substantial importance. T1 mapping is one
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disclose.uch quantitative CMR technique and can be
erformed with or without contrast; the pulse
equence for T1 mapping has been recently im-
roved with shortened breath-hold duration.
he ability to measure differences in T1 with-
ut contrast would also obviate issues raised by
he contrast kinetics due to variable renal func-
ion, contrast agent relaxivity, and pulse sequence
ifferences. In this issue of iJACC, 2 papers dem-
nstrate data in support of native or noncontrast
1 mapping for tissue characterization in various
linical conditions.
In the first, Puntmann et al. (7) compared hy-
ertrophic cardiomyopathy (HCM) and nonisch-
mic dilated cardiomyopathy (DCM) patients
ith control subjects. T1 mapping was performed
rior to and sequentially at 10-min intervals after
ontrast infusion to calculate extracellular volume
ECV) fraction. These authors found that native T1
as significantly longer in cardiomyopathy patients
HCM 1,254  43 ms, and DCM 1,239  57 ms)
han in controls (1,070  55 ms); the accuracy
as high with an area under the receiver operat-
ng curve of 0.99. In fact, native T1 performed
etter than post-contrast T1 and ECV measure-
ents. Thus, in a case of diagnostic dilemma in
hich both morphologic imaging and LGE were
nclear or the patient had stage 4/5 chronic
idney disease, native T1 mapping could clarify
he diagnosis. Although, larger multicenter studies
ill be useful it is a significantly important
nding.
The second paper by Karamitsos et al. (8) is a
tudy of patients with amyloidosis; approximately
ne-half with a definitive diagnosis of cardiac in-
olvement, one-quarter without, and another
uarter with possible involvement. In addition to
ealthy control subjects they also included pa-
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533tients with aortic stenosis (AS) as a set of hyper-
trophic controls. They found that native myocar-
dial T1 was higher in cardiac amyloidosis compared
to normal subjects and AS patients. Interestingly,
their normal values were 958  20 ms, over 100
s shorter than the values in the previously dis-
ussed paper of Puntmann et al. (7). This also
oints to some of the limitations of the T1 map-
ing technique, e.g., variations dependent on
ulse sequence used, scanner manufacturer, and
eld strength used. However, a native T1 value of
,020 ms was 92% accurate for demonstrating
ossible or definite cardiac involvement in amy-
oid patients. This offers promise for the ability to
dentify cardiac amyloid without using contrast in
MR, a considerable advantage given the rela-
ively high incidence of chronic kidney disease in
his population.
The pathophysiologic basis of the elevated T1
alues in these clinical conditions is not well un-
erstood. The link between post-contrast T1
hortening and fibrosis is fairly well-established in
brotic diseases as mentioned above (4). As hy-
othesized by Puntmann et al. (7), the increase in
ative T1 may be due to increased extracellular
olume due to expansion of the interstitial space
rom fibrosis in HCM or fibrillar deposits in
myloidosis. However, it is concerning as to
hy native T1 was not elevated in AS, which is
also associated with fibrosis (8)? Is it specific
for certain disorders? Was fibrosis in the AS
not severe enough? Many such concerns would
need clarification.
Furthermore, significant limitations remain to
the application of T1 mapping in a broad man-
ner. The pulse sequence varies between manufac-
turers, is not presently a product sequence, and is
currently available only at selected centers; T1
values also differ at 1.5-T and 3.0-T field
strengths. Moreover, whereas some laboratories
report T1 values, others measure ECV. Thus, the
pulse sequences and rules of measurement need to
be standardized. A subcommittee of the Society
for Cardiovascular Magnetic Resonance has re-
cently been charged with this responsibility.
These 2 papers (7,8) nicely illustrate the agony
and the ecstasy in cutting edge research and also
the difficult road ahead. The Indian parable of 3
blind men and the elephant is highly applicable— swhat the results mean depends on the perspective
used. Much appears to be a true breakthrough at
first glance including the ability to characterize
cardiac tissue with a simple CMR sequence and
to do so without contrast in patients with renal
dysfunction. The disease could be detected very
early (8), even before current gold standards have
indicated cardiac involvement. However, these
very findings also raise other clinically loaded
questions. Is differentiation between normal and
abnormal (as in the Puntmann paper [7]) using a
sophisticated and costly technique the major need
of the hour in either HCM or DCM? In any
case, these patients already had self evident dis-
ease recognized through other cheaper and widely
used methods. Would the ability of T1 mapping
to distinguish between normal and abnormal then
be called a screening technique subject to the rigid
rules? Should the future premium be placed on
differentiating between type of pathology rather
than normal versus abnormal in the myocardium?
Finally, while eventual studies will clarify this
part, the so what question would need to be an-
wered. What would it mean for therapy and out-
ome? Just documenting that something is abnor-
al, even if detected early on, would have little
enefit unless that information had direct clinical
onsequence. Although at least at this time such a
oal seems far off for noncontrast T1 mapping, it
eeds to be the immediate focus of future re-
earch. The Karamitsos et al. (8) paper raises an-
ther interesting aspect. How do we decide what
s true if the test parameter turns out better than
he gold standard? In patients with amyloidosis,
ut no evidence for cardiac involvement, noncon-
rast T1 values were higher than normal, nearing
hose seen with moderate to severe AS. Is T1
apping a determinant of an early disease not de-
ectable by current approach, or is it just false
ositive? In the absence of a histological correlate
e are only left to speculate. Editors have to of-
en deal with really nascent science. Waiting for a
istologic proof may be very difficult or even im-
ossible to obtain in a robust manner and may
elay publication of potentially important find-
ngs. On the other hand, rapid publication leaves
nagging feeling that the story is incomplete.
These 2 papers illustrate another important is-ue for investigators working on the edge of re-
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534search, as to how to interpret the mechanisms for
what we find in a world without other guideposts,
and when the thinking is juiced with optimism.
Not surprisingly, the most common path is to ex-
trapolate from other similar tests and conditions.
It may be implied that noncontrast T1 mapping
might be an even more sensitive alternative to
LGE. Probably, LGE detects different fibrosis
than that by increased T1 times; the coarse fibro-
sis seen with LGE most certainly also influences
T1 times. Future studies will clarify this and it is
a bit premature to conclude that one is a substi-
tute for another. The second leap of faith com-
mon to many papers in this area is that native T1
increase implies fibrosis. Although there is a
strong association, could one exclude the possibil-
ity of something totally unrelated to fibrosis, or
common to both fibrosis and an altered extracel-
lular matrix (including volume, edema, or un-
known parameters that may influence T1 relaxivity)?opathies. J Cardiovasc Magn Reson
2012;14:54.
3
4
5
the eye of the behold
Cardiol Img 2012;5:amyloidosis without clear cardiac involvement do
have CMR suggested cardiac involvement, one is
not any wiser about what this involvement means.
Finally, these papers also illustrate the cardiac bi-
opsy nature of these early findings. Logistical rea-
sons and convenience limit these studies to focal
slices and similar to a regular biopsy this may be
hit or miss for a patchy pathology. Additional
studies may clarify if these findings still hold true
in the whole heart.
Regardless, T1 mapping comprises an important
part of the imager’s armamentarium for differentiat-
ing cardiomyopathies. It remains to be determined
whether it would supersede the use of LGE or
evolve as an additive approach. It is with confidence
that we state that the age of noninvasive myocardial
biopsy is upon us. We, however, also are acutely
aware that we would need to know what this all
means and how best to use it in clinical practice.
We at JACC: Cardiovascular Imaging promise toThus, while we may conclude that the patients with help you ride along on this cutting edge journey.R E F E R E N C E S
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